Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
Primary Purpose
Polycystic Ovary Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Metformin ER
Sponsored by
About this trial
This is an interventional basic science trial for Polycystic Ovary Syndrome focused on measuring Polycystic Ovary Syndrome, PCOS, Acne, Infertility, Irregular menses, Irregular period, Mitochondria, Metabolism
Eligibility Criteria
Inclusion Criteria:
- Polycystic ovary syndrome
- No hormonal or antidiabetic medications for 1 month
- Good general health
Exclusion Criteria:
- Smoker
- Acute infection or chronic disease
- Diabetes
- Pregnant or trying to get pregnant over next half year
- Bleeding disorders
- Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Metformin
Arm Description
Metformin ER 1500 mg per day treatment for 12 weeks
Outcomes
Primary Outcome Measures
Muscle Metabolism/Mitochondrial Function
The change in mitochondrial activity before and after metformin treatment will be analyzed in relationship to the clinical response to 3 months of metformin treatment (i.e., clinical response to metformin = changes in glucose metabolism, hormone levels, and ovulation response)
Secondary Outcome Measures
Genetic risk variants affecting mitochondrial function/metabolism
Blood will be analyzed for differences in genes between patients and its relationship to mitochondrial function.
Full Information
NCT ID
NCT02198417
First Posted
July 17, 2014
Last Updated
August 14, 2018
Sponsor
Massachusetts General Hospital
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Utah
1. Study Identification
Unique Protocol Identification Number
NCT02198417
Brief Title
Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
Official Title
Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 2014 (undefined)
Primary Completion Date
September 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Utah
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
PCOS occurs when a woman does not release an egg regularly each month, causing her periods to be irregular. Women with PCOS can also have increased hair growth on the face and body, acne, head balding, infertility, pre-diabetes, and diabetes. PCOS is commonly treated with oral contraceptive pills (also known as the birth control pills). Sometimes, a medication called metformin is also used to treat PCOS, especially if a woman has evidence of insulin resistance or if fertility is desired. Unfortunately, metformin works in only some women with PCOS. The mechanism through which metformin works in PCOS is not clear and it difficult to predict who will benefit from metformin treatment and who will not.
The investigators are doing this research study to look at how the medication metformin affects the cells in the body of patients with PCOS. Specifically, the investigators will look at how metformin affects the mitochondria. Mitochondria are the part of cells that produce fuel (energy) for other cells and play a role in metabolism. The investigators would like to see whether there is a relationship between mitochondrial activity and symptoms of polycystic ovary syndrome (PCOS) before and after treatment with metformin. They would also like to study whether genes affect the response to metformin in women with PCOS.
Detailed Description
Women who are eligible to enroll in this study will be treated with the medication metformin for 12 weeks. Before and after treatment with metformin, the following will be assessed:
Weight, blood pressure, waist circumference
Lipids (cholesterol)
Hormone levels (including testosterone and other androgens)
IV glucose tolerance test (to assess for early evidence of insulin resistance)
Effect of metformin on muscle mitochondria (this will involve one MRI scan and one muscle biopsy each before and after treatment with metformin)
Ovulation will be closely monitored at least twice a month with pelvic ultrasounds and blood tests for estrogen and progesterone levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Ovary Syndrome
Keywords
Polycystic Ovary Syndrome, PCOS, Acne, Infertility, Irregular menses, Irregular period, Mitochondria, Metabolism
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Metformin
Arm Type
Experimental
Arm Description
Metformin ER 1500 mg per day treatment for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Metformin ER
Other Intervention Name(s)
Glucophage
Intervention Description
Treatment with metformin ER for 12 weeks
Primary Outcome Measure Information:
Title
Muscle Metabolism/Mitochondrial Function
Description
The change in mitochondrial activity before and after metformin treatment will be analyzed in relationship to the clinical response to 3 months of metformin treatment (i.e., clinical response to metformin = changes in glucose metabolism, hormone levels, and ovulation response)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Genetic risk variants affecting mitochondrial function/metabolism
Description
Blood will be analyzed for differences in genes between patients and its relationship to mitochondrial function.
Time Frame
3 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Polycystic ovary syndrome
No hormonal or antidiabetic medications for 1 month
Good general health
Exclusion Criteria:
Smoker
Acute infection or chronic disease
Diabetes
Pregnant or trying to get pregnant over next half year
Bleeding disorders
Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Corrine Welt, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
24606093
Citation
Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014 May;99(5):1870-8. doi: 10.1210/jc.2013-4021. Epub 2014 Feb 25.
Results Reference
background
Learn more about this trial
Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
We'll reach out to this number within 24 hrs